The total return over the past 12 months is -61.33% vs. +16.94% for the S&P 500. So far it's up -68.66% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (61.23%) | (67.42%) | (73.12%) | (68.75%) | N/A | N/A |
| Total Return CAGR | (61.33%) | (67.44%) | (73.13%) | (68.76%) | N/A | N/A |
| Revenue CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
GT Biopharma, Inc. (GTBP)
| Year | Start price | End price | GTBP Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $19.63 | $6.16 | (68.66%) | +14.51% | (83.17%) |
| 2025 | $76.25 | $19.63 | (74.27%) | +17.72% | (91.99%) |
| 2024 | $191.25 | $76.25 | (60.13%) | +24.89% | (85.02%) |
| 2023 | $664.25 | $191.25 | (71.21%) | +26.19% | (97.40%) |
| 2022 | $2,287.50 | $664.25 | (70.96%) | (18.17%) | (52.79%) |
| 2021 | $5,406.00 | $2,287.50 | (57.69%) | +28.74% | (86.43%) |
| 2020 | $1,032.75 | $5,406.00 | +423.46% | +18.37% | +405.09% |
| 2019 | $8,287.50 | $1,032.75 | (87.54%) | +31.22% | (118.76%) |
| 2018 | $56,737.50 | $8,287.50 | (85.39%) | (4.56%) | (80.83%) |
| 2017 | $367,045.00 | $56,737.50 | (84.54%) | +21.70% | (106.24%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
